Though analysts seemed uncertain in February about the commercial future despite favorable phase III data, they came away upbeat from a meeting last week with Trevena Inc. about injectable Olinvo (oliceridine) for moderate to severe acute pain. H.C. Wainwright's Ed Arce said his firm believes the company "has set its eyes on a realistic and promising target market" for the opioid receptor mu agonist, though Wall Street hardly seemed of that opinion earlier in the year.